Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Cancer Generics Market Opportunities, Analysis & Forecasts, 2022: Patent Expiry of Blockbuster Oncology Drugs & Generic Cancer Drugs Made More Accessible to Developing Countries - Research and Markets

Research and Markets
Posted on: 18 Oct 16

Research and Markets has announced the addition of the "Global Cancer Generics Market Forecast to 2022" report to their offering.

Within the pharmaceutical industry, the oncology market is growing at a rapid pace owing to the rising incidences of cancer. In 2015, 15.2 Million new cancer cases were registered across the globe. This number is forecasted to increase to a value of 19.3 Million by 2025. Furthermore, the patent expiry of blockbuster cancer drugs is another major factor which is propelling the growth of the cancer generics industry.

The global cancer generics market has been segmented on the basis of mode of administration into oral and injectables. Injectables are the most widely used type of cancer generics drugs. The report also highlights the major cancer generic drugs available in the global market.

Furthermore, the global cancer generics market has also been segmented on the basis of the major indications they are used for. According to the report, breast cancer is expected to account for the largest share in 2016 due to presence of large number of generic drugs and rising incidences of this indication.

The last section of the report discusses about the prominent players in global cancer generics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global cancer generics market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Global Cancer Drugs Market Outlook 2022

3.1 Cancer Incidences

3.2 Cancer Drug Market

4. Market Drivers & Challenges

4.1 Drivers

4.1.1 Increasing Cancer Incidences

4.1.2 Strategic Collaborations

4.1.3 Growing Geriatric Population

4.1.4 Ability to Curb Healthcare Cost

4.2 Challenges

4.2.1 Growing Backlog of Generic Drug Applications

4.2.2 Counterfeit Generic Drugs

4.3 Opportunities

4.3.1 Patent Expiry of Blockbuster Oncology Drugs

4.3.2 Generic Cancer Drugs Made More Accessible to Developing Countries

5. Global Cancer Generics Market Analysis 2022

6. Global Cancer Generics Market by Mode of Administration

6.1 Oral Generics

6.2 Injectables Generics

7. Global Cancer Generics Market by Major Indications

7.1 Lung Cancer

7.2 Breast Cancer

7.3 Colorectal Cancer

7.4 Stomach Cancer

7.5 Prostate Cancer

8. Global Cancer Generics Market by Geographic Regions

9. Trends & Developments

9.1 Generic Version of Blockbuster Cancer Drug

9.2 Entry of Indian Generic Cancer Drug in US

10. Mergers & Acquisitions

11. Key Players

11.1 Fresenius Kabi AG

11.2 Pfizer Inc

11.3 Teva Pharmaceutical Industries Ltd

11.4 Mylan N.V

11.5 Sun Pharmaceutical Industries Ltd

11.6 Sandoz International GmbH - A Novartis Company

11.7 Sanofi

11.8 Dr. Reddy's Laboratories Ltd

11.9 Cipla Ltd

11.10 Apotex Inc

For more information about this report visit http://www.researchandmarkets.com/research/kfh8h2/global_cancer

View source version on businesswire.com: http://www.businesswire.com/news/home/20161018005874/en/

Business Wire
www.businesswire.com

Last updated on: 18/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.